Latest Hospitality News

Vicinity Centres delivered a robust third quarter in FY26 with high occupancy and retail sales growth, while successfully extending debt maturity and advancing key developments at Chatswood Chase and Galleria.

NRW Holdings has reaffirmed its FY26 guidance with revenue expected between $4.1 billion and $4.2 billion and underlying EBITA of $275 million to $285 million, supported by a robust $7.5 billion order book and strategic acquisitions in energy transition and digital innovation.

Emyria Limited reported $1.2 million in revenue for the March quarter, driven by insurer-funded clinics and strong clinical outcomes in PTSD treatment. The company is advancing its national clinic rollout, including new sites in Victoria and New South Wales, while launching a global partnership program targeting international drug sponsors.

Imricor Medical Systems has secured A$60 million through a placement to fund its US commercial rollout, regulatory approvals, and clinical programs, boosting its cash reserves to nearly A$103 million.

Entropy Neurodynamics has unveiled a striking 75% response rate in a small Phase 2a trial of its oral psilocybin therapy for treatment-resistant irritable bowel syndrome, far surpassing existing treatments and validating its gut-brain axis approach.

InteliCare has locked in its largest-ever $8.8 million contract with mecwacare to deploy its AI-driven platform across 22 aged care homes, while appointing Angus Cameron as CEO to spearhead growth.

Clarity Pharmaceuticals’ Phase II Co-PSMA trial confirms its Cu-SAR-bisPSMA PET imaging detects more than twice the prostate cancer lesions versus standard care, driving patient management changes. Phase III AMPLIFY recruitment closes, manufacturing deals inked, and cash sits near $198 million.

ReNerve Limited reports a 79% jump in quarterly sales, secures key Asia-Pacific approvals, and progresses its nerve repair pipeline with the NervAlign Nerve Guide Matrix entering Stage 3 development.

IMEXHS Limited kicked off FY26 with a 13% revenue increase and a strategic pivot to an AI-native radiology workflow platform, securing major contracts in Latin America and advancing proprietary AI agents.

4DMedical has made significant strides in commercial adoption of its CT:VQ™ lung imaging technology, securing top US hospital contracts, regulatory approvals in Europe and the UK, and a major pharmaceutical partnership, all backed by strong capital raises and inclusion in the S&P/ASX 200.

Artrya has fully integrated its Salix platform at Tanner Health, is preparing two more US sites for launch, and is finalising FDA submission for its Coronary Flow module, backed by a strong cash position of $76.6 million.

Orthocell has initiated commercial sales of its Remplir nerve repair device in Canada, leveraging a distributor-led model to penetrate a US$75 million market and setting the stage for broader North American expansion.